Buffett's Berkshire cuts U.S. drugmaker stakes, invests in drug royalty company

Go back to Buffett's Berkshire cuts U.S. drugmaker stakes, invests in drug royalty company

Merck (MRK) and Ridgeback to Report Phase 3 Data for Molnupiravir

November 17, 2021 6:01 AM EST

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that new Phase 3 data for molnupiravir, an investigational oral COVID-19 antiviral medicine, will be presented as a late-breaking poster (#LB-5319) at the American Society of Tropical Medicine and Hygiene (ASTMH) 2021 Annual Meeting taking place virtually from Nov. 17-21. Poster data will be available on Wednesday, Nov. 17 at 9 a.m. ET and presented during Poster Session C from 11 a.m.-12:30 p.m. ET on Saturday, Nov. 20.

The presentation will include data from the molnupiravir clinical... More

AbbVie (ABBV) Announces European Commission Approval of SKYRIZI

November 17, 2021 5:06 AM EST

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved SKYRIZI® (risankizumab, 150 mg, subcutaneous injection at week 0, week 4 and every 12 weeks thereafter) alone or in combination with methotrexate (MTX), for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying anti-rheumatic drugs... More